JOP20200329A1 - بروتينات وشظايا سائدة مناعيا في التصلب المتعدد - Google Patents

بروتينات وشظايا سائدة مناعيا في التصلب المتعدد

Info

Publication number
JOP20200329A1
JOP20200329A1 JOP/2020/0329A JOP20200329A JOP20200329A1 JO P20200329 A1 JOP20200329 A1 JO P20200329A1 JO P20200329 A JOP20200329 A JO P20200329A JO P20200329 A1 JOP20200329 A1 JO P20200329A1
Authority
JO
Jordan
Prior art keywords
fragments
multiple sclerosis
immunodominant proteins
immunodominant
proteins
Prior art date
Application number
JOP/2020/0329A
Other languages
English (en)
Inventor
Ramos Mireia Sospedra
Roland Martin
Original Assignee
Universit?T Zurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of JOP20200329A1 publication Critical patent/JOP20200329A1/ar
Application filed by Universit?T Zurich filed Critical Universit?T Zurich

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

غير متوفر
JOP/2020/0329A 2018-06-28 2020-12-20 بروتينات وشظايا سائدة مناعيا في التصلب المتعدد JOP20200329A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180326.3A EP3586866A1 (en) 2018-06-28 2018-06-28 Immunodominant proteins and fragments in multiple sclerosis
PCT/EP2019/067468 WO2020002674A1 (en) 2018-06-28 2019-06-28 Immunodominant proteins and fragments in multiple sclerosis

Publications (1)

Publication Number Publication Date
JOP20200329A1 true JOP20200329A1 (ar) 2019-06-28

Family

ID=62814962

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0329A JOP20200329A1 (ar) 2018-06-28 2020-12-20 بروتينات وشظايا سائدة مناعيا في التصلب المتعدد

Country Status (21)

Country Link
US (2) US12527846B2 (ar)
EP (3) EP3586866A1 (ar)
JP (2) JP2021528965A (ar)
KR (1) KR20210041559A (ar)
CN (2) CN119971002A (ar)
AU (1) AU2019294465A1 (ar)
BR (1) BR112020026458A2 (ar)
CA (1) CA3104231A1 (ar)
CL (1) CL2020003355A1 (ar)
CO (1) CO2020016105A2 (ar)
CR (1) CR20200642A (ar)
EC (1) ECSP20083339A (ar)
ES (1) ES3042684T3 (ar)
IL (1) IL279608A (ar)
JO (1) JOP20200329A1 (ar)
MX (1) MX2020014003A (ar)
PE (1) PE20211739A1 (ar)
PH (1) PH12020552222A1 (ar)
SG (1) SG11202012661WA (ar)
WO (1) WO2020002674A1 (ar)
ZA (1) ZA202007822B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法
JP2024529354A (ja) 2021-07-16 2024-08-06 ウニヴェルジテート・チューリッヒ 多発性硬化症を層別化および処置するための方法
EP4119948A1 (en) 2021-07-16 2023-01-18 Universität Zürich Method for stratification and treatment of multiple sclerosis
EP4611796A1 (en) 2022-11-01 2025-09-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis
EP4553083A1 (en) * 2023-11-10 2025-05-14 Cellerys AG Peptides and their use for the treatment and/or prevention of multiple sclerosis
TW202535910A (zh) * 2023-11-10 2025-09-16 蘇黎世大學 肽及其用於治療及/或預防多發性硬化症之用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5932443A (en) * 1997-09-26 1999-08-03 Incyte Pharmaceuticals, Inc. Human antigens
JP2001145488A (ja) * 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子
US6743904B2 (en) 2001-03-14 2004-06-01 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
EP1407269B1 (en) 2001-06-22 2010-10-20 Burkhard Jansen A method for diagnosing a person having multiple sclerosis
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US20060269917A1 (en) 2002-12-04 2006-11-30 Macina Roberto A Compositions, splice variants and methods relating to colon specific gene and proteins
JP2006141297A (ja) * 2004-11-19 2006-06-08 Eiken Chem Co Ltd 血管新生を検出するためのマーカー
WO2007013359A2 (en) * 2005-07-28 2007-02-01 Oncotherapy Science, Inc. Cancer related gene rasgef1a
JP2009519017A (ja) 2005-12-07 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の治療及び診断
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
WO2009062260A1 (en) 2007-11-15 2009-05-22 David Richmond Booth Therapy for multiple sclerosis
AU2009246134B2 (en) 2008-05-16 2016-03-03 The Children's Hospital Of Philadelphia Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
EP2318020B1 (en) 2008-06-30 2015-08-19 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
EP2437060A1 (de) * 2010-10-01 2012-04-04 Protagen AG Markersequenzen für Multiple Sklerose und deren Verwendung
DE102010042359A1 (de) * 2010-10-12 2012-04-12 Protagen Ag Markersequenzen für Multiple Sklerose und deren Verwendung
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
US20160032344A1 (en) 2013-03-15 2016-02-04 Glycobia, Inc. Polysialic acid, blood group antigens and glycoprotein expression in prokaryotes
EP3043647A4 (en) * 2013-09-12 2017-05-10 Teva Pharmaceutical Industries Ltd. Gene expression biomarkers of laquinimod responsiveness
CN107502615B (zh) * 2017-10-16 2020-05-05 中国海洋大学 海带中编码gdp-甘露糖-4,6-脱水酶的基因、及其蛋白质和用途

Also Published As

Publication number Publication date
EP4640282A3 (en) 2025-12-31
US20210162019A1 (en) 2021-06-03
EP3586866A1 (en) 2020-01-01
KR20210041559A (ko) 2021-04-15
AU2019294465A1 (en) 2021-01-14
CL2020003355A1 (es) 2021-07-23
US20250332229A1 (en) 2025-10-30
ECSP20083339A (es) 2021-03-31
EP3813865B1 (en) 2025-08-06
CR20200642A (es) 2021-04-28
BR112020026458A2 (pt) 2021-05-25
MX2020014003A (es) 2021-03-25
EP4640282A2 (en) 2025-10-29
US12527846B2 (en) 2026-01-20
IL279608A (en) 2021-03-01
SG11202012661WA (en) 2021-01-28
CA3104231A1 (en) 2020-01-02
EP3813865C0 (en) 2025-08-06
PE20211739A1 (es) 2021-09-06
CN119971002A (zh) 2025-05-13
WO2020002674A1 (en) 2020-01-02
JP2021528965A (ja) 2021-10-28
EP3813865A1 (en) 2021-05-05
ZA202007822B (en) 2021-10-27
CN112512554A (zh) 2021-03-16
PH12020552222A1 (en) 2021-06-28
CO2020016105A2 (es) 2021-03-19
JP2024116146A (ja) 2024-08-27
ES3042684T3 (en) 2025-11-24

Similar Documents

Publication Publication Date Title
JOP20200329A1 (ar) بروتينات وشظايا سائدة مناعيا في التصلب المتعدد
CL2021000738A1 (es) Proteínas de fijación a sirpa y métodos de uso de estas
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
IL279897A (en) Fusosome compositions and uses thereof
IL282362A (en) Intein proteins and uses thereof
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
IL283217A (en) Split interleukin mimetics and their use
EP3810172A4 (en) Heterodimeric proteins and uses thereof
MX2025000260A (es) Proteina de union al antigeno anti-steap1
SI3775909T1 (sl) Sredstva in postopki za glikoprofiliranje proteina
EP3544629A4 (en) PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
BR112019012342A2 (pt) anticorpos il-11
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
MX376324B (es) Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos.
MY191944A (en) Binding proteins and methods of use thereof
EP3835418A4 (en) Novel crispr-associated protein and use thereof
IL283942A (en) Tubulysins and protein-tubulysin conjugates
EP3960756A4 (en) FLAGELLIN FUSION PROTEIN AND USE THEREOF
EP3962288C0 (fr) Proteine de legumineuse gelifiante
EP3882277A4 (en) FUSION PROTEIN AND USE THEREOF
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
CL2018000137S1 (es) Implante dental
JOP20210036A1 (ar) مثبطات او- جليكوبروتين-2-أسيتاميدو-2-ديوكسي-3-دي-جلوكوبيرانوسيداز
GT201500266A (es) Matrices reestructuradas de proteina natural